Clinical Trials Logo

Clinical Trial Summary

prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer

Clinical Trial Description

Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement. Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response rate of the neoadjuvant chemotherapy. Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy. The group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT04549584
Study type Observational [Patient Registry]
Source Seoul National University Hospital
Status Terminated
Start date October 1, 2020
Completion date December 16, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05660083 - Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) Phase 2